Non-ST-elevation Acute Coronary Syndrome
Conditions
Interventions
experimental group:Resuvastatin 10mg/day+ilozumab 140mg subcutaneous injection once every two weeks
control group:Resuvastatin 10mg/day
Sponsors
the first affiliated hospital of USTC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)age =18 years at screening (2)NST-ACS,with at least one coronary segment (culprit lesion) requiring PCI (3)LDL-C =70 mg/dL assessed prior to, or during PCI in patients who have been receiving any stable statin regimen within = 4 weeks prior to enrollment; OR LDL-C =130 mg/dL in patients who are statin-na?ve or have not been on stable statin regimen for = 4 weeks prior to enrollment (4)Angiographic evidence of 50% -75% reduction in lumen diameter by angiographic visual estimation (5)Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel (6)Target vessel must not have undergone previous PCI within the target segment (7)Hemodynamic stability allowing the repetitive administration of Nitroglycerine (8)Willingness of patient to undergo follow-up intracoronary imaging
Exclusion criteria
Exclusion criteria: (1)Left-main disease, defined as =50% reduction in lumen diameter of the left main coronary artery by angiographic visual estimation (2)Estimate =75% reduction in lumen diameter of Non-culprit vessel by angiographic visual estimation (3)History of coronary artery bypass surgery or unstable clinical status (hemodynamic instability) (4)Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2 (5)Active liver disease or hepatic dysfunction (6)Known intolerance to rosuvastatin OR known statin intolerance (7)Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel (8)Patients who previously received PCSK9 inhibitor (9)Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening (10)Treatment with systemic steroids or systemic cyclosporine in the past 3 months (11)Active infection or major hematologic, metabolic, or endocrine dysfunction (12)Pregnant or lactating women (13)Estimated life expectancy less than 1 year (14)Unwilling to finish the follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in minimal fibrous cap thickness(FCT); | — |
Secondary
| Measure | Time frame |
|---|---|
| MACCE;Change in lipid levels;Absolute change in the average of minimum FCT for all images;;Absolute change in maximum lipid arc throughout the segment;Absolute change in maximum lipid length throughout the segment;macrophage grading; | — |
Countries
China
Contacts
Public ContactWu jiawei
the first affliated hospital of USTC
Outcome results
None listed